See the DrugPatentWatch profile for cosentyx

The MMR (measles, mumps, and rubella) vaccine might be postponed in individuals taking Cosentyx (secukinumab) due to potential implications related to the immune system. Cosentyx is a medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug known as a biologic, which works by targeting specific proteins in the immune system [1].

The MMR vaccine is a live attenuated vaccine, meaning it contains weakened forms of the measles, mumps, and rubella viruses [2]. Since Cosentyx can affect the immune system's function, there could be a risk that the vaccine may not work as effectively in individuals taking this medication [3]. Moreover, there might be an increased risk of adverse effects from the vaccine due to the weakened immune system [3].

Therefore, healthcare providers might decide to postpone MMR vaccination until a patient is no longer taking Cosentyx or has completed a sufficient wash-out period after discontinuing the medication [3]. It is essential to consult a healthcare professional for personalized advice regarding vaccinations and medication use [3].

Sources:

[1] Cosentyx. (n.d.). Retrieved from <https://www.cosentyx.com/>

[2] Measles, Mumps, and Rubella (MMR) Vaccine. (2021, August 12). Retrieved from <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html>

[3] DrugPatentWatch. (n.d.). Cosentyx (secukinumab): DrugBank, FDA, Clinical Trials, Patents, Reviews, and More. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>